New targets for small molecules in inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 11, Issue 5, 2015, Pages 338-340

  Hanauer, Stephen B ^b   Sandborn, William J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; MONGERSEN; SMAD7 PROTEIN; SPHINGOSINE 1 PHOSPHATE; TOFACITINIB;

CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; INFLAMMATORY BOWEL DISEASE; NOTE; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84929395653     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(3):603-617.
2. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015;372(12):1104-1113.
3. Sandborn W, Feagan B, Wolf D, et al. The TOUCHSTONE study: a randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe ulcerative colitis. Gastroenterology. In press.
4. Sandborn WJ, Ghosh S, Panes J, et al; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616-624.
5. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W; Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014;12(9):1485-1493.e2.
6. Sands BE. New drugs on the horizon for IBD. Dig Dis. 2014;32(suppl 1):74-81.